文献速递泌尿生殖与妇科肿瘤放疗

局部晚期前列腺癌根治性前列腺切除术前新辅助立体定向体部放疗的Ⅰ期试验

A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-22

单机构Ⅰ期试验纳入高危或淋巴结阳性前列腺癌男性,评估根治性前列腺切除术前新辅助立体定向体部放疗的最大耐受剂量。术后30天内25%(n=4)出现剂量限制性毒性,但因晚期不良事件的比例和严重程度提前终止(计划38例中入组16例)。结论为新辅助立体定向体部放疗后行根治性前列腺切除术导致不可接受的高毒性和严重生活质量下降。

要点

  • 术后30天内25%(n=4)出现剂量限制性毒性。
  • 术后3级泌尿生殖毒性和胃肠毒性分别发生于75%(n=12)和25%(n=4)。
  • 因晚期不良事件的比例和严重程度提前终止(计划38例中入组16例)。

核心结论

  • 新辅助立体定向体部放疗后行根治性前列腺切除术导致不可接受的高毒性和严重生活质量下降。

研究设计与样本

  • 单机构Ⅰ期试验(NCT02946008),纳入高危或淋巴结阳性前列腺癌男性,2017年3月至10月入组,计划38例中实际入组16例。

主要发现

  • 中位随访40个月(范围33-44),术后30天内25%(n=4)出现剂量限制性毒性。
  • 术后3级泌尿生殖毒性和胃肠毒性分别发生于75%(n=12)和25%(n=4)。
  • 两名患者在根治性前列腺切除术后≥2年需要膀胱切除和尿流改道。
  • 根治性前列腺切除术后24个月,75%(n=12)男性每天使用≥1个尿垫,0%有适合性交的勃起。
  • 所有患者手术切缘阴性,31%(n=5)对新辅助立体定向体部放疗有完全或部分(术前)MRI反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验因晚期不良事件的比例和严重程度提前终止(计划38例中入组16例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Men with locally advanced prostate cancer who undergo radical prostatectomy (RP) often develop recurrence and require postoperative radiotherapy. We aimed to determine the safety of neoadjuvant stereotactic body radiotherapy (SBRT) before RP in this population. METHODS AND PATIENTS: A single-institution phase 1 trial (NCT02946008) of men with high-risk or node-positive prostate cancer were enrolled between March and October 2017. The primary endpoint was to determine the maximum tolerated dose of SBRT based on a composite 30-day post-RP toxicity goal of ≤28% of patients experiencing a dose-limiting toxicity (DLT). Secondary outcomes included toxicity, efficacy, and multiple quality of life (QoL) inventories. SBRT (30-35 Gy/5 fractions) was delivered to the prostate and seminal vesicles, and 25 Gy/5 fractions to the pelvic lymph nodes. RP was performed for a median of 6 weeks post-SBRT. Hormone therapy was not allowed. RESULTS: Median follow-up was 40 months (range, 33-44). Twenty-five percent of the patients (n = 4) experienced a DLT within 30 days post-RP; however, the trial was stopped early (n = 16 of planned 38 patients) owing to the proportion and severity of the late adverse events. Post-RP grade 3 genitourinary and gastrointestinal toxicities occurred in 75% (n = 12) and 25% (n = 4) of patients, respectively. Two patients required cystectomy and urinary diversion ≥2 years post-RP. At 24 months post-RP, 75% (n = 12) of men used ≥1 pad/d and 0% had erections suitable for intercourse. Surgical margins were negative in all patients and 31% (n = 5) had complete or partial (pre-RP) MRI-response to SBRT. Three-year biochemical recurrence and distant metastasis were 45% (95% CI, 5%-68%) and 28% (95% CI, 0%-49%), respectively. CONCLUSIONS: Neoadjuvant SBRT followed by RP resulted in unacceptably high toxicity and severe QoL declines.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hammer L, Jiang R, Hearn J, et al. A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35878714. doi:10.1016/j.ijrobp.2022.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。